Schütz, Ekkehard

[["dc.bibliographiccitation.firstpage","1240"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Genes"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Gladbach, Yvonne Saara"],["dc.contributor.author","Sklarz, Lisa-Madeleine"],["dc.contributor.author","Roolf, Catrin"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Fuellen, Georg"],["dc.contributor.author","Junghanss, Christian"],["dc.contributor.author","Murua Escobar, Hugo"],["dc.contributor.author","Hamed, Mohamed"],["dc.date.accessioned","2022-09-01T09:51:11Z"],["dc.date.available","2022-09-01T09:51:11Z"],["dc.date.issued","2022"],["dc.description.abstract","Little is known about optimally applying chemotherapeutic agents in a specific temporal sequence to rapidly reduce the tumor load and to improve therapeutic efficacy. The clinical optimization of drug efficacy while reducing side effects is still restricted due to an incomplete understanding of the mode of action and related tumor relapse mechanisms on the molecular level. The molecular characterization of transcriptomic drug signatures can help to identify the affected pathways, downstream regulated genes and regulatory interactions related to tumor relapse in response to drug application. We tried to outline the dynamic regulatory reprogramming leading to tumor relapse in relapsed MLL-rearranged pro-B-cell acute lymphoblastic leukemia (B-ALL) cells in response to two first-line treatments: dexamethasone (Dexa) and cytarabine (AraC). We performed an integrative molecular analysis of whole transcriptome profiles of each treatment, specifically considering public knowledge of miRNA regulation via a network-based approach to unravel key driver genes and miRNAs that may control the relapse mechanisms accompanying each treatment. Our results gave hints to the crucial regulatory roles of genes leading to Dexa-resistance and related miRNAs linked to chemosensitivity. These genes and miRNAs should be further investigated in preclinical models to obtain more hints about relapse processes."],["dc.identifier.doi","10.3390/genes13071240"],["dc.identifier.pii","genes13071240"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113900"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","2073-4425"],["dc.title","Molecular Characterization of the Response to Conventional Chemotherapeutics in Pro-B-ALL Cell Lines in Terms of Tumor Relapse"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","173"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Theriogenology"],["dc.bibliographiccitation.lastpage","179"],["dc.bibliographiccitation.volume","79"],["dc.contributor.author","Mayer, Jennifer"],["dc.contributor.author","Soller, Jan T."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Purwins, Vanessa"],["dc.contributor.author","Wemheuer, Wilhelm E."],["dc.contributor.author","Schuetz, Ekkehard"],["dc.contributor.author","Brenig, Bertram"],["dc.date.accessioned","2018-11-07T09:30:51Z"],["dc.date.available","2018-11-07T09:30:51Z"],["dc.date.issued","2013"],["dc.description.abstract","Early and accurate pregnancy diagnosis in dairy cattle is a prerequisite for successful herd management. However, most of the currently available methods allow an early diagnosis only approximately 30 days after insemination. Recently, circulating nucleic acids (CNAs) have been used successfully as biomarkers in prenatal diagnosis at different gestational stages in human and animals. Here we show that CNAs can also be used as markers for the detection of early pregnancy in cattle. Serum samples were collected from multiparous pregnant (N = 24) and nonpregnant (N = 16) dairy cows at different days after insemination (Days 0, 20, and 40). Isolated serum DNA was preprocessed using a modified serial analysis of gene expression technique, which generated concatemerized short sequence tags for downstream next generation sequencing. Bioinformatic analysis identified sequence tags specific for pregnant dairy cows at Day 20 after insemination. The identified CNA-tags originated from repetitive regions of the bovine genome. Tag sequences that showed increased hit counts per animal were used to design quantitative real-time polymerase chain reaction assays. These quantitative polymerase chain reaction assays were applied to CNA samples from matched pregnant (N = 12) and nonpregnant cows (N = 16) at different times after insemination (Day 0, 20, and 40). At Day 20 after insemination the quantities of the interspersed repeats Art2A and BovB were increased in the pregnant cows compared with the nonpregnant control cows (P < 0.05). The best performing CNA biomarker BovB yielded an area under the receiver operating characteristic curve of 0.76. At a defined cutoff value, the pregnant and the control groups can be distinguished with a sensitivity of 83% and specificity of 75%. These results suggest that CNAs can be used as biomarkers for the detection of early pregnancy in cattle. (C) 2013 Elsevier Inc. All rights reserved."],["dc.description.sponsorship","European Regional Development Fund (ERDF) [W2-80025700]"],["dc.identifier.doi","10.1016/j.theriogenology.2012.09.024"],["dc.identifier.isi","000312607400022"],["dc.identifier.pmid","23122603"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31408"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0093-691X"],["dc.title","Early pregnancy diagnosis in dairy cows using circulating nucleic acids"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","58"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Veterinary Quarterly"],["dc.bibliographiccitation.lastpage","67"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Zhang, Xuying"],["dc.contributor.author","Hirschfeld, Marc"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kupke, Alexandra"],["dc.contributor.author","Köhler, Kernt"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Brenig, Bertram"],["dc.date.accessioned","2020-12-10T18:14:48Z"],["dc.date.available","2020-12-10T18:14:48Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1080/01652176.2020.1721611"],["dc.identifier.eissn","1875-5941"],["dc.identifier.issn","0165-2176"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74619"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteogenesis imperfecta in a male holstein calf associated with a possible oligogenic origin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.lastpage","176"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.editor","Oellerich, Michael"],["dc.contributor.editor","Dasgupta, Amitava"],["dc.date.accessioned","2020-05-22T06:58:17Z"],["dc.date.available","2020-05-22T06:58:17Z"],["dc.date.issued","2016"],["dc.description.abstract","Genome transplant dynamics is a particularly promising new approach for the detection of graft injury based on the determination of graft-derived circulating cell-free DNA (cfDNA) in the blood of the recipient. An increase of donor DNA is an early indication of organ damage. A novel potential routine assay for graft-derived circulating cfDNA quantification has been developed using droplet digital polymerase chain reaction for the determination of the donor/recipient circulating cfDNA ratio. This method is very cost-effective and provides results on the same day. Monitoring graft-derived cfDNA has the advantage that it directly interrogates the health of the donor organ, and it allows early detection of transplant injury (“liquid biopsy”). The detection of subclinical rejection would be desirable to allow early intervention. Undiagnosed chronic damage can result in chronic rejection. The determination of graft-derived circulating cfDNA may complement or possibly replace other approaches for post-transplant monitoring, and it may improve the chances of long-term graft survival. This method will be helpful to individualize immunosuppressive regimens. Personalized immunosuppression will in the future shift emphasis from reaction to prevention, which could make immunosuppressive drugs safer and more effective and also reduce the cost of health care."],["dc.identifier.doi","10.1016/B978-0-12-800885-0.00007-2"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65676"],["dc.language.iso","en"],["dc.publisher","Elsevier"],["dc.publisher.place","San Diego"],["dc.relation.doi","10.1016/C2013-0-19247-1"],["dc.relation.isbn","978-0-12-800885-0"],["dc.relation.ispartof","Personalized Immunosuppression in Transplantation"],["dc.title","Graft-derived cell-free DNA as a marker of graft integrity after transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Sensen, Maria"],["dc.contributor.author","Gordon, Paul M. K."],["dc.contributor.author","Schuetz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Urnovitz, Howard B."],["dc.contributor.author","Brenig, Bertram"],["dc.contributor.author","Groschup, Martin H."],["dc.contributor.author","Sutton, Ted"],["dc.contributor.author","Church, Robert B."],["dc.contributor.author","Sensen, Christoph W."],["dc.date.accessioned","2018-11-07T08:42:00Z"],["dc.date.available","2018-11-07T08:42:00Z"],["dc.date.issued","2010"],["dc.format.extent","221"],["dc.identifier.isi","000285872300276"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19600"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Landes Bioscience"],["dc.publisher.place","Austin"],["dc.relation.issn","1933-6896"],["dc.title","Identification of DNA Patterns from Circulating Nucleic Acids related to Bovine Spongiform Encephalopathy (BSE)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Nature Reviews Nephrology"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Sherwood, Karen"],["dc.contributor.author","Keown, Paul"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Stegbauer, Johannes"],["dc.contributor.author","Rump, Lars Christian"],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2021-06-01T09:41:41Z"],["dc.date.available","2021-06-01T09:41:41Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1038/s41581-021-00428-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85002"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1759-507X"],["dc.relation.issn","1759-5061"],["dc.title","Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","373"],["dc.bibliographiccitation.lastpage","386"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Blum, Anna"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.editor","Preedy, V. R."],["dc.contributor.editor","Patel, V. B."],["dc.date.accessioned","2020-05-22T07:14:29Z"],["dc.date.available","2020-05-22T07:14:29Z"],["dc.date.issued","2017"],["dc.description.abstract","Improvement of long-term patient and graft outcome is still a challenge in liver transplantation. Personalized approaches to immunosuppressive treatment of liver transplant patients are currently under investigation, as conventional markers have limited usefulness to predict drug efficacy. The presence of graft-derived cell-free DNA (GcfDNA) in the plasma of liver transplant recipients opens up the possibility of monitoring allograft injury through measurement of this molecular marker. A rapid, cost-effective droplet digital PCR (ddPCR) method has been developed for the quantification of donor DNA. GcfDNA has shown to be useful for the detection of subclinical and full-blown acute rejection and non-rejection-related liver injury (e.g., HCV infection, liver trauma, ischemia/reperfusion damage). GcfDNA allows for the early detection of transplant injury (“liquid biopsy”) and enables earlier more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression."],["dc.identifier.doi","10.1007/978-94-007-7675-3_10"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65684"],["dc.language.iso","en"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.eisbn","978-94-007-7675-3"],["dc.relation.isbn","978-94-007-7674-6"],["dc.relation.ispartof","Biomarkers in Liver Disease"],["dc.title","Graft-derived cell-free DNA as a biomarker in liver transplantation"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","6642"],["dc.bibliographiccitation.issue","15_suppl"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","6642"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Kuhlmann, Alexander"],["dc.contributor.author","Weiss, Glen J."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Westphal, Ronja"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Graf von der Schulenburg, J.-Matthias"],["dc.date.accessioned","2020-12-10T18:41:36Z"],["dc.date.available","2020-12-10T18:41:36Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1200/JCO.2019.37.15_suppl.6642"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77627"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cost-minimization analysis of using tumor cell-free DNA as monitoring tool in cancer immunotherapy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Critical Reviews in Clinical Laboratory Sciences"],["dc.bibliographiccitation.lastpage","218"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Schütz, Ekkehard"],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Kanzow, Philipp"],["dc.contributor.author","Plowman, Piers N."],["dc.contributor.author","Weiss, Glen J."],["dc.contributor.author","Walson, Philip D."],["dc.date.accessioned","2018-11-07T10:24:20Z"],["dc.date.accessioned","2020-05-22T07:29:56Z"],["dc.date.available","2018-11-07T10:24:20Z"],["dc.date.available","2020-05-22T07:29:56Z"],["dc.date.issued","2017"],["dc.description.abstract","High-quality genomic analysis is critical for personalized pharmacotherapy in patients with cancer. Tumor-specific genomic alterations can be identified in cell-free DNA (cfDNA) from patient blood samples and can complement biopsies for real-time molecular monitoring of treatment, detection of recurrence, and tracking resistance. cfDNA can be especially useful when tumor tissue is unavailable or insufficient for testing. For blood-based genomic profiling, next-generation sequencing (NGS) and droplet digital PCR (ddPCR) have been successfully applied. The US Food and Drug Administration (FDA) recently approved the first such \"liquid biopsy\" test for EGFR mutations in patients with non-small cell lung cancer (NSCLC). Such non-invasive methods allow for the identification of specific resistance mutations selected by treatment, such as EGFR T790M, in patients with NSCLC treated with gefitinib. Chromosomal aberration pattern analysis by low coverage whole genome sequencing is a more universal approach based on genomic instability. Gains and losses of chromosomal regions have been detected in plasma tumor-specific cfDNA as copy number aberrations and can be used to compute a genomic copy number instability (CNI) score of cfDNA. A specific CNI index obtained by massive parallel sequencing discriminated those patients with prostate cancer from both healthy controls and men with benign prostatic disease. Furthermore, androgen receptor gene aberrations in cfDNA were associated with therapeutic resistance in metastatic castration resistant prostate cancer. Change in CNI score has been shown to serve as an early predictor of response to standard chemotherapy for various other cancer types (e.g. NSCLC, colorectal cancer, pancreatic ductal adenocarcinomas). CNI scores have also been shown to predict therapeutic responses to immunotherapy. Serial genomic profiling can detect resistance mutations up to 16 weeks before radiographic progression. There is a potential for cost savings when ineffective use of expensive new anticancer drugs is avoided or halted. Challenges for routine implementation of liquid biopsy tests include the necessity of specialized personnel, instrumentation, and software, as well as further development of quality management (e.g. external quality control). Validation of blood-based tumor genomic profiling in additional multicenter outcome studies is necessary; however, cfDNA monitoring can provide clinically important actionable information for precision oncology approaches."],["dc.description.sponsorship","Chronix Biomedical"],["dc.identifier.doi","10.1080/10408363.2017.1299683"],["dc.identifier.isi","000401250100004"],["dc.identifier.pmid","28393575"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/65692"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1549-781X"],["dc.relation.issn","1040-8363"],["dc.title","Using circulating cell-free DNA to monitor personalized cancer therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S75"],["dc.bibliographiccitation.journal","Therapeutic Drug Monitoring"],["dc.bibliographiccitation.lastpage","S79"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Oellerich, Michael"],["dc.contributor.author","Walson, Philip D."],["dc.contributor.author","Beck, Julia"],["dc.contributor.author","Schmitz, Jessica"],["dc.contributor.author","Kollmar, Otto"],["dc.contributor.author","Schütz, Ekkehard"],["dc.date.accessioned","2020-12-10T18:19:52Z"],["dc.date.available","2020-12-10T18:19:52Z"],["dc.date.issued","2016"],["dc.description.abstract","Although short-term success after solid organ transplantation is good, long-term graft and recipient survival are both not satisfactory. Despite therapeutic drug monitoring (TDM) of immunosuppressive drugs (ISDs), both excessive and insufficient immunosuppression still do occur. There is a need for new biomarkers that, when combined with TDM, can be used to provide more effective and less toxic, personalized immunosuppression to improve long-term survival. Currently used methods are insufficient to rapidly, cost-effectively, and directly interrogate graft integrity after solid organ transplantation. However, because organ transplants are also genome transplants, measurement of graft-derived circulating cell-free DNA (GcfDNA) has shown promise as a way to improve both graft and recipient outcomes after solid organ transplantation through the early detection of severe graft injury, enabling an early intervention. A newly developed droplet digital polymerase chain reaction (ddPCR) method has advantages over expensive high-throughput sequencing methods to rapidly quantify GcfDNA percentages and absolute amounts. This procedure does not require donor DNA and therefore can be applied to any organ donor/recipient pair. The droplet digital polymerase chain reaction method allows for the early, sensitive, specific, and cost-effective direct assessment of graft integrity and can be used to define individual responses to ISDs including the minimal ISD exposures necessary to prevent rejection. This is especially important in patients undergoing ISD switches due to ISD toxicity, infections, or malignancies. Although prospective, multicenter clinical trials in liver, heart, and kidney transplantation have not been completed, early results suggest that GcfDNA can be combined with TDM to guide changes in immunosuppression to provide more effective, and less toxic treatment. Personalized immunosuppression will shift emphasis in transplantation from reaction to prevention and could improve outcome at lower health care costs."],["dc.identifier.doi","10.1097/FTD.0000000000000239"],["dc.identifier.isi","000377003400009"],["dc.identifier.issn","0163-4356"],["dc.identifier.pmid","26418703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75409"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-3694"],["dc.relation.issn","0163-4356"],["dc.title","Graft-Derived Cell-Free DNA as a Marker of Transplant Graft Injury"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]